Vansa Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 19 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.77 Cr
- Satisfied Charges ₹ 2.50 M
- Revenue Growth 48.83%
- Profit Growth 38.79%
- Ebitda 24.84%
- Net Worth 29.99%
- Total Assets 13.69%
About Vansa Biotech
Vansa Biotech Private Limited (VBPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 13 September 2005 and has a history of 19 years and five months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹4.77 Cr. The company has closed loans amounting to ₹2.50 M, as per Ministry of Corporate Affairs (MCA) records.
Santosh Shukla, Vinod Doodhnath, and Neha Shukla serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24230MH2005PTC156000
- Company No.
156000
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Sep 2005
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Vansa Biotech?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Santosh Shukla  | Director | 13-Sep-2005 | Current |
| Vinod Doodhnath | Additional Director | 01-Aug-2017 | Current |
| Neha Shukla | Director | 09-Jul-2019 | Current |
Financial Performance of Vansa Biotech.
Vansa Biotech Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 48.83% increase. The company also saw a substantial improvement in profitability, with a 38.79% increase in profit. The company's net worth Soared by an impressive increase of 29.99%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vansa Biotech?
In 2023, Vansa Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹47.75 M
₹2.50 M
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 3.54 Cr
- Others : 1.23 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Jan 2021 | Axis Bank Limited | ₹3.54 Cr | Open |
| 04 Jan 2021 | Others | ₹1.23 Cr | Open |
| 23 Oct 2012 | Bank Of Baroda | ₹2.50 M | Satisfied |
How Many Employees Work at Vansa Biotech?
Unlock and access historical data on people associated with Vansa Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vansa Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vansa Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
